circadian rhythm is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Roger discovers clues about the robots' origins; they and the Motilene (the city's power source) are from space, there are two different robot variants that each have their own language, and the robots are self-aware. He then meets a disassembled friendly robot named Watson who reveals that Dr. Faraday has been kidnapping and reprogramming the robots for slavery because Wellington Wells is running out of food and no one farms anymore. Roger aims to both save Faraday and help the robots. James, however, still thinks Faraday is doing something for the good of mankind and is growing to no longer trust Roger. Roger destroys the reprogramming chamber, causing Faraday to see him as a threat, and decides to destroy the robots' portal. Roger tries to go to the portal chamber, but James stops him. Roger knocks him out and activates the security systems at the entrance to the portal. Faraday controls a Headmistress, a giant robotic supervisor, to stop his interference. James changes his mind and helps Roger defeat her. Watson and a few robots meet them to congratulate the two and bring Faraday back home to be "reprogrammed". Roger asks to come with them; Watson agrees but informs Roger that if he wants to return home, the portal will only open onto a different time. Roger can then choose to bring James with him or not. If he decides to bring James, the two men will share a kiss and walk together through the portal. If he decides to go without James, he will bid him farewell and say he hopes to see James again.
=== Social issues === In 2023, Celia Medrano described Bukele's positions on social issues as "flexible" ("flexibles") and a "liquid ideology" ("ideología líquida"). She explained that Bukele changes his positions to appease as many voters as possible and to gauge public opinion on issues such as same-sex marriage and abortion. Bukele stated in 2014 that he was an ally of the LGBT community, supported their civil rights, and opposed discrimination against LGBT individuals. In August 2021, Bukele proposed constitutional reform to legalize same-sex marriage in El Salvador. The proposal would have changed text in the constitution that defined marriage as being between "a man and a woman" ("hombre y mujer") to defining marriage as between "spouses" ("cónyuges"), and would have prohibited discrimination based on sexual orientation. The earliest Bukele's proposal could have gone into effect would have been 2027, since it would have to be approved by two consecutive sessions of the Legislative Assembly. Bukele stated the following month that the proposed constitutional reform would not legalize same-sex marriage, posting on Facebook that the original text would remain intact. In March 2024, Bukele stated that his government would remove "all traces" of "gender ideologies in schools and colleges". In June 2024, Bukele fired 300 bureaucrats from the ministry of culture for promoting policies that were "incompatible" with his emphasis on "patriotic and family values". El Salvador has one of the world's strictest abortion laws, banning it in all circumstances with no exceptions.
General elections were held in Thailand on 8 February 2026 in order to determine the composition of the House of Representatives. A referendum was also held on the same day so as to determine whether the 2017 constitution should be replaced with a new one. After the 2023 general election, three coalition governments were formed by the resulting parliament. After an initial attempt by the progressive Move Forward Party was blocked by the Senate, the Pheu Thai Party split off to form governments with conservative and pro-military parties, first under Srettha Thavisin and later under Paetongtarn Shinawatra. Both governments collapsed, with Srettha removed by a court ruling in 2024 and Paetongtarn dismissed by the Constitutional Court in 2025. In September 2025, an agreement was made between the People's Party and Bhumjaithai Party to support Anutin Charnvirakul as prime minister, with a requirement for Anutin to dissolve the House within 4 months after the presentation of the government's policy platform. The House was dissolved on 12 December 2025, with a snap election being required within 60 days. The election was scheduled for 8 February 2026, the latest possible date. The election resulted in the Bhumjaithai Party winning the most seats in the House of Representatives, with 192. The People's Party, led by Natthaphong Ruengpanyawut, followed in second place with 120 seats. Pheu Thai, led by Yodchanan Wongsawat, came in third with 74 seats. There was a drop in turnout, which was 4.22 percentage points down compared to the last election.
Sources: en.wikipedia.org
mRNA-based disease diagnosis technologies are diagnostic procedures using messenger RNAs. as molecular diagnostic tools to discover the relationships between patient's DNAs and their specific biological features. The mRNA-based disease diagnosis technologies have been applied to medical field widely in recent years, especially on early diagnosis of tumors (such as renal cell carcinoma, hepatocellular carcinoma, breast cancer and prostate cancer). The technology can be applied to various types of samples depending on how easily the samples are accessible and whether the samples reliably contain the mRNA that related to specific diseases. For example, in hepatocellular carcinoma, the tumor tissues excised during the operation are a good resource for mRNA-based test to analysis. Among those most commonly used samples, blood sample is one of the most easily accessible via minimally invasive method. degenerative diseases . Blood has been used in early diagnosis of some cancers, such as non-small lung cancer and neuroendocrine tumors.
This detection method uses mammalian antibodies to bind to microbial toxins which can then be processed in a variety of different ways. Of the commercial ways of using immunochemical detection would be enzyme-linked immunosorbent assays (ELISA). This assay has the advantage of being able to screen for a broad range of toxins but could have issues with specificity depending on the antibody used. A more exotic setup involves the use of CdS quantum dots which are used in an electro-chemiluminescent immunosensor. A major aspect of immunochemical methods being tested in laboratories are uses of nanowires and other nanomaterials to detect microbial toxins.
37. Ugeskr Laeger. 2011 Mar 28;173(13):975. [Melanotan-induced lentigines and nevi]. [Article in Danish] Thestrup-Pedersen K(1), Søndergaard K. Author information: (1)Hudklinikken, 4800 Nykøbing Falster, Denmark. ktp56@hotmail.com A 25-year-old man had self-injected more than 150 doses of melanotan to increase his skin pigmentation, which had increased significantly. At the same time, his nevi had become darker and new nevi and lentigines developed; they also occurred on his genitals causing his referral. Two nevi were excised, but showed no signs of malignant transformation.
=== Cosmetics === Collagen is a protein found in many tissues of the body, such as cartilage, bone, tendons, and skin (including around hair follicles, and nail beds). Collagen cremes are marketed as cosmetics even though collagen cannot penetrate the skin because its fibers are too large. Partially hydrolyzed forms of collagen and low molecular weight collagen peptides, such as glycyl-prolyl-hydroxyproline, are more commonly used in cosmetics products than collagen itself in the unproven belief that topical absorption is improved. Skin aging involves changes in the extracellular matrix rather than changes in collagen alone. Intrinsic aging is associated with dermal thinning, loss and alteration of collagen, degeneration of the elastic fiber network, and reduced hydration. Chronic ultraviolet exposure further alters the organization of dermal collagen and elastic fibers, producing characteristic changes associated with photoaging. Because collagen and elastin contribute different mechanical properties to the dermal extracellular matrix, preservation of both networks is important for maintaining skin structure and elasticity.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.